We are pleased to invite investors and analysts to participate in our virtual event on Tuesday, 8 June 2021, highlighting Roche data presented at the ASCO21 Virtual Scientific Program June 4 - 8 2021. 16:00 - 17:30 CEST / 15:00 - 16:30 BST 10:00 - 11:30 am EDT / 7:00 - 3:30 am PDT The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 3pm CEST on the day of the event. >click here Access to virtual event (pre-registration required) Please pre-register for our webinar here*. Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com. A replay of the webcast will be available via >ir.roche.com | |
Best regards, Karl Mahler Head of Investor Relations | Sabine Borngräber Investor Relations Officer |
Roche Investor Relations | |
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com |
Jon Kaspar Bayard Phone: +41 61 68-83894 e-mail: jon_kaspar.bayard@roche.com |
Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com |
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com |
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com |
Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com |
Investor Relations North America | |
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com |
Dr. Lisa Tuomi Phone: +1 650 467 8737 e-mail: tuomi.lisa@gene.com |
Attachments
- Original document
- Permalink
Disclaimer
Roche Holding AG published this content on 30 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 April 2021 12:03:07 UTC.